Atossa Therapeutics Receives Buy Rating from HC Wainwright

HC Wainwright has reaffirmed a "buy" rating for Atossa Therapeutics (NASDAQ:ATOS) in their latest research note released to investors on Thursday. The analysts have set a target price of $6.00 for the stock. This target suggests a potential upside of approximately 337.96% based on the stock's current trading price.

Recent Analyst Activities

Atossa Therapeutics has also been reviewed by other financial analysts recently. Ascendiant Capital Markets previously raised their price target from $6.25 to $6.50 while maintaining a "buy" rating in a note published on September 11. Meanwhile, StockNews.com upgraded its rating for Atossa Therapeutics from "sell" to "hold" on October 25.

Stock Performance Overview

On Thursday, the shares of Atossa Therapeutics decreased by $0.04, landing at $1.37. During the day, approximately 230,103 shares were exchanged, which is below the average trading volume of 1,086,837 shares. Currently, Atossa Therapeutics has a market cap of about $172.29 million, a price-to-earnings (PE) ratio of -5.75, and a beta of 1.20. The company's 50-day moving average stands at $1.43, with a 200-day moving average at $1.38. Over the past year, their shares have ranged from a low of $0.62 to a high of $2.31.

Insights on Earnings

Atossa Therapeutics recently disclosed their quarterly earnings on August 12, reporting earnings per share (EPS) of ($0.05), which exceeded the analysts' expectations of ($0.06) by $0.01. Analysts project that the company will have an EPS of -$0.22 for the ongoing fiscal year.

Institutional Ownership Trends

In terms of institutional investment, several firms have adjusted their stakes in Atossa Therapeutics. For instance, Vanguard Group Inc. increased its holdings by 1.4% during the first quarter, acquiring an additional 78,269 shares, bringing their total to 5,753,993 shares valued at approximately $10.36 million. Virtu Financial LLC took a new position in the company worth approximately $151,000 during the same quarter. Other significant movements include Bank of New York Mellon Corp, which boosted its ownership by over 3,160% in the second quarter, adding 399,041 shares to reach a total of 411,667 shares valued at roughly $490,000.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments in oncology with a specific aim at addressing unmet medical needs related to breast cancer and other conditions affecting women. The lead drug candidate in their pipeline is oral (Z)-endoxifen, a metabolite derived from tamoxifen, which is currently in Phase II clinical trials for the treatment and prevention of breast cancer.

Atossa, Therapeutics, Rating